EYP-1901 for Wet Age-Related Macular Degeneration

EYP-1901 for Wet Age-Related Macular Degeneration
51%40%29%May 18May 19May 20May 21May 22May 23May 24May 25May 26May 27May 27 • YES 39.5%
EyePoint Pharmaceuticals, Inc. ($EYPT)
No stock close$13.61$12.52$11.44May 18May 19May 20May 21May 22May 23May 24May 25May 26May 27May 18 • EYPT $11.70May 19 • EYPT $11.82May 20 • EYPT $12.50May 21 • EYPT $12.78May 22 • EYPT $12.93May 26 • EYPT $13.35May 27 • EYPT $13.16

Will this trial show a positive result on Average change in best corrected visual acuity (BCVA), Weeks 52 and 56?

Paper Trading
Create account to trade
ClinicalNewsTrialPositionsReasoningOracle
Primary Completion
10/1/26
Study Completion
10/1/27
Sponsor
EyePoint Pharmaceuticals, Inc.
Ticker
$EYPT
Type
Phase 3
Trial Status
Active Not Recruiting
Trial Size
400
NCT
NCT06683742
Trial Description
This Phase 3 trial compares EYP-1901 with aflibercept in wet age-related macular degeneration, measuring vision change at one year.